QTTB

8.3401.65%
MM

Maria Marzilli

Chief Business Officer

Ms. Maria Marzilli is Chief Business Officer of Q32 Bio Inc. Ms. Marzilli was Executive Vice President of Corporate Strategy & Program Operations of Q32 Bio Inc. from 2023. Ms. Marzilli was Vice President of Corporate Development & Portfolio Strategy of Q32 Bio Inc. from 2022 to 2023. Ms. Marzilli was VP of Corporate Development & Program Management of Q32 Bio Inc. from 2022 to 2022. Ms. Marzilli was Head of Corporate Development of Q32 Bio Inc. until 2022. She joined Q32 Bio from Agios Pharmaceuticals, where she was responsible for Portfolio Strategy and Alliance Management. In that role, she led cross-functional teams tasked with driving portfolio investment decisions and key assessments to inform the company’s overall strategy, business development activities and geographic footprint. She also managed the metabolic immuno-oncology partnership with Celgene, ensuring alignment on strategic and operational goals and priorities. Prior to Agios, Maria held roles of increasing responsibility at Biogen, beginning in Corporate Strategy and supporting the refinement and implementation of the company’s vision and then moving to Global Market Access, where she helped support pricing and strategy decisions for portfolio programs as well as build out a world class Market Access team. Earlier in her career, she held roles at both Genzyme Corporation and Decision Resources. Maria received her B.A. in Biology from Harvard University and an M.P.H. in Health Services from the Boston University School of Public Health.

Positions